Evolution
to Gene Therapy
GluGene Therapeutics is pioneering the development of state-of-the-art AAV vectors
with superiority to conventional vectors through combining two emerging technologies:
i) directed evolution that can design customized AAV vectors with key features as therapeutic carriers,
such as “organ/cell-specific delivery”, “resistance to pre-existing antibody”, and “high packaging efficiency” and
ii) machine learning that can predict capsid-crossovers having novel functions
and expand the scopes of AAV-mediated gene therapy applications.
Linkage
to Gene Therapy
Inspired by the chemical principle of adhesives molecules, GluGene Therapeutics produces assembled, supramolecular AAV complexes to address the limitations of existing AAV technology.
